10-Q Filing

REGENXBIO INC. CIK: 1590877 Q2 2016

Filing Information

Form Type	10-Q
Accession Number	`0001564590-16-023492`
Period End Date	20160630
Filing Date	20160809
Fiscal Year	2016
Fiscal Period	Q2
XBRL Instance	rgnx-20160630.xml

Filing Contents

This filing contains the following financial statements:

Balance Sheet 68 Income Statement 86 Cash Flow Statement 56

Balance Sheet 68 line items

Line Item	Tag	Value	Unit	Period
Preferred stock, par value	`PreferredStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Preferred stock, par value	`PreferredStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Preferred stock, shares authorized	`PreferredStockSharesAuthorized`	10.00M	shares	Point-in-time
Preferred stock, shares authorized	`PreferredStockSharesAuthorized`	10.00M	shares	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$54.12M	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$85.22M	USD	Point-in-time
Preferred stock, shares issued	`PreferredStockSharesIssued`	0.00	shares	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$1.12M	USD	Point-in-time
Preferred stock, shares issued	`PreferredStockSharesIssued`	0.00	shares	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$30.08M	USD	Point-in-time
Preferred stock, shares outstanding	`PreferredStockSharesOutstanding`	0.00	shares	Point-in-time
Preferred stock, shares outstanding	`PreferredStockSharesOutstanding`	0.00	shares	Point-in-time
Marketable securities	`MarketableSecuritiesCurrent`	$64.12M	USD	Point-in-time
Marketable securities	`MarketableSecuritiesCurrent`	$60.02M	USD	Point-in-time
Common stock, par value	`CommonStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Accounts receivable	`AccountsReceivableGrossCurrent`	$2.14M	USD	Point-in-time
Accounts receivable	`AccountsReceivableGrossCurrent`	$783.00K	USD	Point-in-time
Common stock, par value	`CommonStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Common stock, shares authorized	`CommonStockSharesAuthorized`	100.00M	shares	Point-in-time
Prepaid expenses	`PrepaidExpenseCurrent`	$1.48M	USD	Point-in-time
Common stock, shares authorized	`CommonStockSharesAuthorized`	100.00M	shares	Point-in-time
Prepaid expenses	`PrepaidExpenseCurrent`	$1.02M	USD	Point-in-time
Other current assets	`OtherAssetsCurrent`	$851.00K	USD	Point-in-time
Common stock, shares issued	`CommonStockSharesIssued`	26.31M	shares	Point-in-time
Common stock, shares issued	`CommonStockSharesIssued`	26.46M	shares	Point-in-time
Other current assets	`OtherAssetsCurrent`	$1.44M	USD	Point-in-time
Common stock, shares outstanding	`CommonStockSharesOutstanding`	26.31M	shares	Point-in-time
Total current assets	`AssetsCurrent`	$97.91M	USD	Point-in-time
Common stock, shares outstanding	`CommonStockSharesOutstanding`	26.46M	shares	Point-in-time
Total current assets	`AssetsCurrent`	$118.15M	USD	Point-in-time
Marketable securities	`MarketableSecuritiesNoncurrent`	$104.51M	USD	Point-in-time
Marketable securities	`MarketableSecuritiesNoncurrent`	$102.23M	USD	Point-in-time
Property and equipment, net	`PropertyPlantAndEquipmentNet`	$2.86M	USD	Point-in-time
Property and equipment, net	`PropertyPlantAndEquipmentNet`	$538.00K	USD	Point-in-time
Cost method investments	`CostMethodInvestments`	$300.00K	USD	Point-in-time
Cost method investments	`CostMethodInvestments`	$300.00K	USD	Point-in-time
Restricted cash	`RestrictedCashAndCashEquivalentsNoncurrent`	$225.00K	USD	Point-in-time
Other assets	`OtherAssetsNoncurrent`	$266.00K	USD	Point-in-time
Other assets	`OtherAssetsNoncurrent`	$168.00K	USD	Point-in-time
Total assets	`Assets`	$206.07M	USD	Point-in-time
Total assets	`Assets`	$221.38M	USD	Point-in-time
Accounts payable	`AccountsPayableCurrent`	$2.08M	USD	Point-in-time
Accounts payable	`AccountsPayableCurrent`	$1.01M	USD	Point-in-time
Accrued expenses and other current liabilities	`AccruedExpensesAndOtherCurrentLiabilities`	$3.20M	USD	Point-in-time
Accrued expenses and other current liabilities	`AccruedExpensesAndOtherCurrentLiabilities`	$7.07M	USD	Point-in-time
Advance payments	`CustomerAdvancesCurrent`	$127.00K	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$4.34M	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$9.15M	USD	Point-in-time
Deferred rent, net of current portion	`DeferredRentCreditNoncurrent`	$233.00K	USD	Point-in-time
Deferred rent, net of current portion	`DeferredRentCreditNoncurrent`	$748.00K	USD	Point-in-time
Total liabilities	`Liabilities`	$9.90M	USD	Point-in-time
Total liabilities	`Liabilities`	$4.57M	USD	Point-in-time
Commitments and contingencies (Note 6)	`CommitmentsAndContingencies`	-	USD	Point-in-time
Commitments and contingencies (Note 6)	`CommitmentsAndContingencies`	-	USD	Point-in-time
Preferred stock; $0.0001 par value; 10,000 shares authorized, and no shares issued and outstanding at June 30, 2016 and December 31, 2015	`PreferredStockValue`	-	USD	Point-in-time
Preferred stock; $0.0001 par value; 10,000 shares authorized, and no shares issued and outstanding at June 30, 2016 and December 31, 2015	`PreferredStockValue`	-	USD	Point-in-time
Common stock; $0.0001 par value; 100,000 shares authorized at June 30, 2016 and December 31, 2015; 26,463 and 26,313 shares issued and outstanding at June 30, 2016 and December 31, 2015, respectively	`CommonStockValue`	$3.00K	USD	Point-in-time
Common stock; $0.0001 par value; 100,000 shares authorized at June 30, 2016 and December 31, 2015; 26,463 and 26,313 shares issued and outstanding at June 30, 2016 and December 31, 2015, respectively	`CommonStockValue`	$3.00K	USD	Point-in-time
Additional paid-in capital	`AdditionalPaidInCapitalCommonStock`	$269.14M	USD	Point-in-time
Additional paid-in capital	`AdditionalPaidInCapitalCommonStock`	$272.48M	USD	Point-in-time
Accumulated other comprehensive income (loss)	`AccumulatedOtherComprehensiveIncomeLossNetOfTax`	$-719.00K	USD	Point-in-time
Accumulated other comprehensive income (loss)	`AccumulatedOtherComprehensiveIncomeLossNetOfTax`	$521.00K	USD	Point-in-time
Accumulated deficit	`RetainedEarningsAccumulatedDeficit`	$-76.83M	USD	Point-in-time
Accumulated deficit	`RetainedEarningsAccumulatedDeficit`	$-51.62M	USD	Point-in-time
Total stockholders equity	`StockholdersEquity`	$216.81M	USD	Point-in-time
Total stockholders equity	`StockholdersEquity`	$196.18M	USD	Point-in-time
Total liabilities and stockholders equity	`LiabilitiesAndStockholdersEquity`	$206.07M	USD	Point-in-time
Total liabilities and stockholders equity	`LiabilitiesAndStockholdersEquity`	$221.38M	USD	Point-in-time

Income Statement 86 line items

Line Item	Tag	Value	Unit	Period
License revenue	`LicensesRevenue`	$470.00K	USD	1 Quarter
License revenue	`LicensesRevenue`	$570.00K	USD	2 Qtrs
License revenue	`LicensesRevenue`	$2.25M	USD	1 Quarter
License revenue	`LicensesRevenue`	$2.57M	USD	2 Qtrs
License revenue from related party	`RevenueFromRelatedParties`	$1.00M	USD	2 Qtrs
License revenue from related party	`RevenueFromRelatedParties`	$1.00M	USD	1 Quarter
Reagent sales	`OtherSalesRevenueNet`	$166.00K	USD	2 Qtrs
Reagent sales	`OtherSalesRevenueNet`	$148.00K	USD	2 Qtrs
Reagent sales	`OtherSalesRevenueNet`	$44.00K	USD	1 Quarter
Reagent sales	`OtherSalesRevenueNet`	$107.00K	USD	1 Quarter
Grant revenue	`GrantsRevenueExpenses`	$-151.00K	USD	1 Quarter
Grant revenue	`GrantsRevenueExpenses`	$29.00K	USD	2 Qtrs
Grant revenue	`GrantsRevenueExpenses`	$23.00K	USD	1 Quarter
Grant revenue	`GrantsRevenueExpenses`	$289.00K	USD	2 Qtrs
Total revenues	`Revenues`	$2.38M	USD	1 Quarter
Total revenues	`Revenues`	$1.36M	USD	1 Quarter
Total revenues	`Revenues`	$2.01M	USD	2 Qtrs
Total revenues	`Revenues`	$2.77M	USD	2 Qtrs
Licensing costs (including amounts to related parties)	`RelatedPartyCosts`	$314.00K	USD	2 Qtrs
Licensing costs (including amounts to related parties)	`RelatedPartyCosts`	$294.00K	USD	1 Quarter
Licensing costs (including amounts to related parties)	`RelatedPartyCosts`	$449.00K	USD	1 Quarter
Licensing costs (including amounts to related parties)	`RelatedPartyCosts`	$515.00K	USD	2 Qtrs
Costs of reagent sales (including amounts to related parties)	`CostOfGoodsSold`	$79.00K	USD	2 Qtrs
Costs of reagent sales (including amounts to related parties)	`CostOfGoodsSold`	$49.00K	USD	2 Qtrs
Costs of reagent sales (including amounts to related parties)	`CostOfGoodsSold`	$16.00K	USD	1 Quarter
Costs of reagent sales (including amounts to related parties)	`CostOfGoodsSold`	$49.00K	USD	1 Quarter
Research and development (including amounts to related parties)	`ResearchAndDevelopmentExpense`	$4.01M	USD	1 Quarter
Research and development (including amounts to related parties)	`ResearchAndDevelopmentExpense`	$6.80M	USD	2 Qtrs
Research and development (including amounts to related parties)	`ResearchAndDevelopmentExpense`	$16.86M	USD	2 Qtrs
Research and development (including amounts to related parties)	`ResearchAndDevelopmentExpense`	$10.68M	USD	1 Quarter
General and administrative (including amounts to related parties)	`GeneralAndAdministrativeExpense`	$3.40M	USD	1 Quarter
General and administrative (including amounts to related parties)	`GeneralAndAdministrativeExpense`	$6.17M	USD	1 Quarter
General and administrative (including amounts to related parties)	`GeneralAndAdministrativeExpense`	$11.65M	USD	2 Qtrs
General and administrative (including amounts to related parties)	`GeneralAndAdministrativeExpense`	$5.11M	USD	2 Qtrs
Other operating expenses (income)	`OtherOperatingIncomeExpenseNet`	$-17.00K	USD	2 Qtrs
Other operating expenses (income)	`OtherOperatingIncomeExpenseNet`	$20.00K	USD	1 Quarter
Other operating expenses (income)	`OtherOperatingIncomeExpenseNet`	$60.00K	USD	1 Quarter
Other operating expenses (income)	`OtherOperatingIncomeExpenseNet`	$134.00K	USD	2 Qtrs
Total operating expenses	`CostsAndExpenses`	$28.97M	USD	2 Qtrs
Total operating expenses	`CostsAndExpenses`	$7.66M	USD	1 Quarter
Total operating expenses	`CostsAndExpenses`	$12.30M	USD	2 Qtrs
Total operating expenses	`CostsAndExpenses`	$17.33M	USD	1 Quarter
Loss from operations	`OperatingIncomeLoss`	$-14.95M	USD	1 Quarter
Loss from operations	`OperatingIncomeLoss`	$-26.20M	USD	2 Qtrs
Loss from operations	`OperatingIncomeLoss`	$-10.29M	USD	2 Qtrs
Loss from operations	`OperatingIncomeLoss`	$-6.30M	USD	1 Quarter
Investment income	`InvestmentIncomeNet`	$8.00K	USD	2 Qtrs
Investment income	`InvestmentIncomeNet`	$515.00K	USD	1 Quarter
Investment income	`InvestmentIncomeNet`	$998.00K	USD	2 Qtrs
Investment income	`InvestmentIncomeNet`	$6.00K	USD	1 Quarter
Interest expense	`InterestExpense`	$20.00K	USD	2 Qtrs
Total other income (expense)	`NonoperatingIncomeExpense`	$6.00K	USD	1 Quarter
Total other income (expense)	`NonoperatingIncomeExpense`	$-12.00K	USD	2 Qtrs
Total other income (expense)	`NonoperatingIncomeExpense`	$998.00K	USD	2 Qtrs
Total other income (expense)	`NonoperatingIncomeExpense`	$515.00K	USD	1 Quarter
Net loss	`NetIncomeLoss`	$-14.44M	USD	1 Quarter
Net loss	`NetIncomeLoss`	$-10.30M	USD	2 Qtrs
Net loss	`NetIncomeLoss`	$-6.29M	USD	1 Quarter
Net loss	`NetIncomeLoss`	$-25.20M	USD	2 Qtrs
Unrealized gain on available-for-sale securities	`OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax`	$246.00K	USD	1 Quarter
Unrealized gain on available-for-sale securities	`OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax`	$1.24M	USD	2 Qtrs
Total other comprehensive income	`OtherComprehensiveIncomeLossNetOfTax`	$1.24M	USD	2 Qtrs
Total other comprehensive income	`OtherComprehensiveIncomeLossNetOfTax`	$246.00K	USD	1 Quarter
Comprehensive loss	`ComprehensiveIncomeNetOfTax`	$-6.29M	USD	1 Quarter
Comprehensive loss	`ComprehensiveIncomeNetOfTax`	$-23.96M	USD	2 Qtrs
Comprehensive loss	`ComprehensiveIncomeNetOfTax`	$-14.19M	USD	1 Quarter
Comprehensive loss	`ComprehensiveIncomeNetOfTax`	$-10.30M	USD	2 Qtrs
Net loss	`NetIncomeLoss`	$-14.44M	USD	1 Quarter
Net loss	`NetIncomeLoss`	$-10.30M	USD	2 Qtrs
Net loss	`NetIncomeLoss`	$-6.29M	USD	1 Quarter
Net loss	`NetIncomeLoss`	$-25.20M	USD	2 Qtrs
Net accretion and dividends on convertible preferred stock	`PreferredStockDividendsAndOtherAdjustments`	$2.50M	USD	1 Quarter
Net accretion and dividends on convertible preferred stock	`PreferredStockDividendsAndOtherAdjustments`	$1.75M	USD	2 Qtrs
Net gain on extinguishment of convertible preferred stock	`NetGainOnExtinguishmentOfPreferredStockForEarningsPerShare`	$759.00K	USD	2 Qtrs
Net loss applicable to common stockholders	`NetIncomeLossAvailableToCommonStockholdersBasic`	$-14.44M	USD	1 Quarter
Net loss applicable to common stockholders	`NetIncomeLossAvailableToCommonStockholdersBasic`	$-25.20M	USD	2 Qtrs
Net loss applicable to common stockholders	`NetIncomeLossAvailableToCommonStockholdersBasic`	$-11.29M	USD	2 Qtrs
Net loss applicable to common stockholders	`NetIncomeLossAvailableToCommonStockholdersBasic`	$-8.79M	USD	1 Quarter
Basic and diluted net loss per common share	`EarningsPerShareBasicAndDiluted`	$-4.21	USD	2 Qtrs
Basic and diluted net loss per common share	`EarningsPerShareBasicAndDiluted`	$-0.55	USD	1 Quarter
Basic and diluted net loss per common share	`EarningsPerShareBasicAndDiluted`	$-0.96	USD	2 Qtrs
Basic and diluted net loss per common share	`EarningsPerShareBasicAndDiluted`	$-3.24	USD	1 Quarter
Weighted-average basic and diluted common shares	`WeightedAverageNumberOfShareOutstandingBasicAndDiluted`	2.71M	shares	1 Quarter
Weighted-average basic and diluted common shares	`WeightedAverageNumberOfShareOutstandingBasicAndDiluted`	26.34M	shares	2 Qtrs
Weighted-average basic and diluted common shares	`WeightedAverageNumberOfShareOutstandingBasicAndDiluted`	26.36M	shares	1 Quarter
Weighted-average basic and diluted common shares	`WeightedAverageNumberOfShareOutstandingBasicAndDiluted`	2.68M	shares	2 Qtrs

Cash Flow Statement 56 line items

Line Item	Tag	Value	Unit	Period
Net loss	`NetIncomeLoss`	$-14.44M	USD	1 Quarter
Net loss	`NetIncomeLoss`	$-10.30M	USD	2 Qtrs
Net loss	`NetIncomeLoss`	$-6.29M	USD	1 Quarter
Net loss	`NetIncomeLoss`	$-25.20M	USD	2 Qtrs
Stock-based compensation expense	`ShareBasedCompensation`	$3.20M	USD	2 Qtrs
Stock-based compensation expense	`ShareBasedCompensation`	$711.00K	USD	2 Qtrs
Net amortization of premiums and accretion of discounts on marketable debt securities	`AccretionAmortizationOfDiscountsAndPremiumsInvestments`	$-987.00K	USD	2 Qtrs
Depreciation and amortization	`DepreciationAndAmortization`	$15.00K	USD	2 Qtrs
Depreciation and amortization	`DepreciationAndAmortization`	$104.00K	USD	2 Qtrs
Unrealized foreign currency transaction gains	`ForeignCurrencyTransactionGainLossUnrealized`	$7.00K	USD	2 Qtrs
Imputed interest on related party promissory notes	`ImputedInterestOnRelatedPartyDebt`	$13.00K	USD	2 Qtrs
Accounts receivable	`IncreaseDecreaseInAccountsReceivable`	$-1.19M	USD	2 Qtrs
Accounts receivable	`IncreaseDecreaseInAccountsReceivable`	$-1.35M	USD	2 Qtrs
Prepaid expenses	`IncreaseDecreaseInPrepaidExpense`	$460.00K	USD	2 Qtrs
Prepaid expenses	`IncreaseDecreaseInPrepaidExpense`	$1.14M	USD	2 Qtrs
Other current assets	`IncreaseDecreaseInOtherCurrentAssets`	$586.00K	USD	2 Qtrs
Other assets	`IncreaseDecreaseInOtherOperatingAssets`	$40.00K	USD	2 Qtrs
Other assets	`IncreaseDecreaseInOtherOperatingAssets`	$98.00K	USD	2 Qtrs
Accounts payable	`IncreaseDecreaseInAccountsPayableTrade`	$585.00K	USD	2 Qtrs
Accounts payable	`IncreaseDecreaseInAccountsPayableTrade`	$930.00K	USD	2 Qtrs
Accrued expenses and other current liabilities	`IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities`	$1.07M	USD	2 Qtrs
Accrued expenses and other current liabilities	`IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities`	$2.98M	USD	2 Qtrs
Other related party payables	`IncreaseDecreaseInDueToOtherRelatedPartiesCurrent`	$-1.88M	USD	2 Qtrs
Advance payments	`IncreaseDecreaseInCustomerAdvances`	$-21.00K	USD	2 Qtrs
Advance payments	`IncreaseDecreaseInCustomerAdvances`	$-127.00K	USD	2 Qtrs
Deferred rent	`IncreaseDecreaseInDeferredRentPayable`	$134.00K	USD	2 Qtrs
Deferred rent	`IncreaseDecreaseInDeferredRentPayable`	$601.00K	USD	2 Qtrs
Net cash used in operating activities	`NetCashProvidedByUsedInOperatingActivitiesContinuingOperations`	$-9.68M	USD	2 Qtrs
Net cash used in operating activities	`NetCashProvidedByUsedInOperatingActivitiesContinuingOperations`	$-16.32M	USD	2 Qtrs
Restricted cash	`IncreaseDecreaseInRestrictedCash`	$225.00K	USD	2 Qtrs
Purchases of marketable securities	`PaymentsToAcquireMarketableSecurities`	$32.26M	USD	2 Qtrs
Maturities of marketable securities	`ProceedsFromSaleAndMaturityOfMarketableSecurities`	$26.13M	USD	2 Qtrs
Purchases of property and equipment	`PaymentsToAcquirePropertyPlantAndEquipment`	$1.49M	USD	2 Qtrs
Purchases of property and equipment	`PaymentsToAcquirePropertyPlantAndEquipment`	$315.00K	USD	2 Qtrs
Net cash used in investing activities	`NetCashProvidedByUsedInInvestingActivitiesContinuingOperations`	$-7.85M	USD	2 Qtrs
Net cash used in investing activities	`NetCashProvidedByUsedInInvestingActivitiesContinuingOperations`	$-315.00K	USD	2 Qtrs
Proceeds from exercise of stock options	`ProceedsFromStockOptionsExercised`	$92.00K	USD	2 Qtrs
Proceeds from exercise of stock options	`ProceedsFromStockOptionsExercised`	$130.00K	USD	2 Qtrs
Issuance costs for initial public offering	`PaymentsOfStockIssuanceCosts`	$25.00K	USD	2 Qtrs
Net cash provided by financing activities	`NetCashProvidedByUsedInFinancingActivitiesContinuingOperations`	$130.00K	USD	2 Qtrs
Net cash provided by financing activities	`NetCashProvidedByUsedInFinancingActivitiesContinuingOperations`	$94.09M	USD	2 Qtrs
Net increase (decrease) in cash and cash equivalents	`CashAndCashEquivalentsPeriodIncreaseDecrease`	$84.09M	USD	2 Qtrs
Net increase (decrease) in cash and cash equivalents	`CashAndCashEquivalentsPeriodIncreaseDecrease`	$-24.03M	USD	2 Qtrs
Beginning of period	`CashAndCashEquivalentsAtCarryingValue`	$54.12M	USD	Point-in-time
Beginning of period	`CashAndCashEquivalentsAtCarryingValue`	$85.22M	USD	Point-in-time
Beginning of period	`CashAndCashEquivalentsAtCarryingValue`	$1.12M	USD	Point-in-time
Beginning of period	`CashAndCashEquivalentsAtCarryingValue`	$30.08M	USD	Point-in-time
End of period	`CashAndCashEquivalentsAtCarryingValue`	$54.12M	USD	Point-in-time
End of period	`CashAndCashEquivalentsAtCarryingValue`	$85.22M	USD	Point-in-time
End of period	`CashAndCashEquivalentsAtCarryingValue`	$1.12M	USD	Point-in-time
End of period	`CashAndCashEquivalentsAtCarryingValue`	$30.08M	USD	Point-in-time
Cash paid for interest	`InterestPaid`	$7.00K	USD	2 Qtrs
Purchases of property and equipment in accounts payable and accrued expenses	`CapitalExpendituresIncurredButNotYetPaid`	$12.00K	USD	2 Qtrs
Purchases of property and equipment in accounts payable and accrued expenses	`CapitalExpendituresIncurredButNotYetPaid`	$939.00K	USD	2 Qtrs
Deferred issuance costs for initial public offering in accrued expenses	`DeferredIssuanceCostsForInitialPublicOfferingInAccruedExpenses`	$1.03M	USD	2 Qtrs
Conversion of related party promissory notes into Series C convertible preferred stock	`DebtConversionConvertedInstrumentAmount1`	$1.39M	USD	2 Qtrs

Data is extracted from SEC EDGAR XBRL filings. Values shown are as reported in the filing.